PREDICTING HUMAN TUMOR RESPONSE BY 31P MRS

描述：此应用程序来自DU。这个项目的总体目标是 建议评估从31-P得出的参数的能力 磁共振波谱(MRS)和核磁共振成像 (MRI)评估预后和监测治疗效果 肿瘤性疾病患者。申请者将在当地学习 术前化疗联合化疗治疗晚期乳腺癌 放射+热疗。为了实现这一目标，申请者 建议在一项研究设计中研究1H MR1图像引导的31-P MRS 它将系列研究与稳健的三维光谱相结合 与磁共振图像具有空间相关性的定位。这项研究将是 作为一项前瞻性、合作性的临床研究试验 结合定义明确的临床终点和技术质量 控制力。使用31-P MRS，申请者将测量肿瘤 磷代谢水平、pH和衍生适当的代谢 指标。使用1H MR1，申请者将测量肿瘤T@和 估计初始肿瘤坏死的体积百分比 用顺磁性造影剂增强，如Magnevist或Prohance。 在启动之前将执行序列MR1和MRS 化疗，在第一次放疗前0-48小时，0-48 在第一次热疗后的几个小时，在24-96个小时之前 去做手术。MRAS和MR1数据将与临床和 对治疗的组织学反应。可行的假设是 治疗前和治疗后近端31-P-MRS代谢物水平、pH和 T2值将预测治疗结果。

DESCRIPTION: This application is from DU. The overall goal of this proposal is to evaluate the ability of parameters derived from 31-P magnetic resonance spectroscopy (MRS) and 1H magnetic resonance imaging (MRI) to assess prognosis and monitor therapeutic effectiveness in patients with neoplastic disease. The applicants will study locally advanced breast cancer treated with preoperative chemotherapy and radiation + hyperthermia. To accomplish this goal, the applicants propose to investigate 1H MR1 image guided 31-P MRS in a study design which incorporates serial studies with robust three dimensional spectral localization with spatial correlation to MR images. This study will be undertaken as a prospective, cooperative clinical research trial incorporating well defined clinical endpoints and technical quality control. With 31-P MRS, the applicants will measure tumor phosphometabolite levels, pH and derive appropriate metabolic indicators. With 1H MR1, the applicants will measure tumor T@ and estimate initial tumor necrosis as the volume percent which does not enhance with a paramagnetic contrast agent, e.g. Magnevist or Prohance. Serial MR1 and MRS will be performed prior to initiation of chemotherapy, 0-48 hours prior to the first radiation treatment, 0-48 hours following the first hyperthermia treatment, and 24-96 hours prior to surgery. The MRAS and MR1 data will be correlated with clinical and histologic response to therapy. The working hypotheses are that pretherapy and proximal posththerapy 31-P MRS metabolite levels, pH, and t2 values will be prognostic of treatment outcome.